JP2013527760A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013527760A5 JP2013527760A5 JP2013508445A JP2013508445A JP2013527760A5 JP 2013527760 A5 JP2013527760 A5 JP 2013527760A5 JP 2013508445 A JP2013508445 A JP 2013508445A JP 2013508445 A JP2013508445 A JP 2013508445A JP 2013527760 A5 JP2013527760 A5 JP 2013527760A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- antigen
- lentiviral
- vsv
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002245 particle Substances 0.000 claims 42
- 108091007433 antigens Proteins 0.000 claims 28
- 102000036639 antigens Human genes 0.000 claims 28
- 239000000427 antigen Substances 0.000 claims 26
- 108090000623 proteins and genes Proteins 0.000 claims 22
- 235000018102 proteins Nutrition 0.000 claims 21
- 102000004169 proteins and genes Human genes 0.000 claims 21
- 201000004792 malaria Diseases 0.000 claims 17
- 244000045947 parasite Species 0.000 claims 17
- 150000001875 compounds Chemical class 0.000 claims 13
- 108091033319 polynucleotide Proteins 0.000 claims 13
- 102000040430 polynucleotide Human genes 0.000 claims 13
- 239000002157 polynucleotide Substances 0.000 claims 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims 13
- 229920001184 polypeptide Polymers 0.000 claims 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims 12
- 108010003533 Viral Envelope Proteins Proteins 0.000 claims 10
- 239000013612 plasmid Substances 0.000 claims 10
- 208000030852 Parasitic disease Diseases 0.000 claims 9
- 230000003053 immunization Effects 0.000 claims 9
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 claims 8
- 101710091045 Envelope protein Proteins 0.000 claims 8
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 8
- 241000713666 Lentivirus Species 0.000 claims 8
- 108010052285 Membrane Proteins Proteins 0.000 claims 8
- 102000018697 Membrane Proteins Human genes 0.000 claims 8
- 101710188315 Protein X Proteins 0.000 claims 8
- 108010027225 gag-pol Fusion Proteins Proteins 0.000 claims 8
- 238000002649 immunization Methods 0.000 claims 8
- 230000036281 parasite infection Effects 0.000 claims 8
- 230000007170 pathology Effects 0.000 claims 8
- 230000010354 integration Effects 0.000 claims 7
- 230000000069 prophylactic effect Effects 0.000 claims 7
- 101710117490 Circumsporozoite protein Proteins 0.000 claims 6
- 108010057081 Merozoite Surface Protein 1 Proteins 0.000 claims 6
- 208000015181 infectious disease Diseases 0.000 claims 6
- 108020004414 DNA Proteins 0.000 claims 5
- 241000223960 Plasmodium falciparum Species 0.000 claims 5
- 230000024932 T cell mediated immunity Effects 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 210000003936 merozoite Anatomy 0.000 claims 5
- 101710203310 Apical membrane antigen 1 Proteins 0.000 claims 4
- 108020004705 Codon Proteins 0.000 claims 4
- 239000013613 expression plasmid Substances 0.000 claims 4
- 230000028993 immune response Effects 0.000 claims 4
- 210000004185 liver Anatomy 0.000 claims 4
- 230000001105 regulatory effect Effects 0.000 claims 4
- 230000035897 transcription Effects 0.000 claims 4
- 238000013518 transcription Methods 0.000 claims 4
- 241000224016 Plasmodium Species 0.000 claims 3
- 101710179519 Ring-infected erythrocyte surface antigen Proteins 0.000 claims 3
- 230000005867 T cell response Effects 0.000 claims 3
- 230000001939 inductive effect Effects 0.000 claims 3
- 238000004806 packaging method and process Methods 0.000 claims 3
- 238000010839 reverse transcription Methods 0.000 claims 3
- 210000003046 sporozoite Anatomy 0.000 claims 3
- YURDCJXYOLERLO-LCYFTJDESA-N (2E)-5-methyl-2-phenylhex-2-enal Chemical compound CC(C)C\C=C(\C=O)C1=CC=CC=C1 YURDCJXYOLERLO-LCYFTJDESA-N 0.000 claims 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 2
- 101710172314 Aspartate-rich protein Proteins 0.000 claims 2
- 101150052200 CS gene Proteins 0.000 claims 2
- 101100532584 Clostridium perfringens (strain 13 / Type A) sspC1 gene Proteins 0.000 claims 2
- 101710091366 Clustered-asparagine-rich protein Proteins 0.000 claims 2
- 108091026890 Coding region Proteins 0.000 claims 2
- 102100029095 Exportin-1 Human genes 0.000 claims 2
- 101100095550 Homo sapiens SENP7 gene Proteins 0.000 claims 2
- 241000725303 Human immunodeficiency virus Species 0.000 claims 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 2
- 102000014842 Multidrug resistance proteins Human genes 0.000 claims 2
- 108050005144 Multidrug resistance proteins Proteins 0.000 claims 2
- 241000223810 Plasmodium vivax Species 0.000 claims 2
- 101150098865 SSP2 gene Proteins 0.000 claims 2
- 102100031406 Sentrin-specific protease 7 Human genes 0.000 claims 2
- 101710192036 Sporozoite surface protein 2 Proteins 0.000 claims 2
- 101000836473 Streptococcus pneumoniae serotype 4 (strain ATCC BAA-334 / TIGR4) Oligopeptide-binding protein AliA Proteins 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 238000004873 anchoring Methods 0.000 claims 2
- 229960001230 asparagine Drugs 0.000 claims 2
- 235000009582 asparagine Nutrition 0.000 claims 2
- 230000002950 deficient Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 210000003743 erythrocyte Anatomy 0.000 claims 2
- 210000003617 erythrocyte membrane Anatomy 0.000 claims 2
- 108700002148 exportin 1 Proteins 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 101710189301 101 kDa malaria antigen Proteins 0.000 claims 1
- 101710197318 Asparagine-rich protein Proteins 0.000 claims 1
- 101100457021 Caenorhabditis elegans mag-1 gene Proteins 0.000 claims 1
- 102000014914 Carrier Proteins Human genes 0.000 claims 1
- 102000012286 Chitinases Human genes 0.000 claims 1
- 108010022172 Chitinases Proteins 0.000 claims 1
- 101710169423 Circumsporozoite protein-related antigen Proteins 0.000 claims 1
- 102000005927 Cysteine Proteases Human genes 0.000 claims 1
- 108010005843 Cysteine Proteases Proteins 0.000 claims 1
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 claims 1
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 101710169678 Histidine-rich protein Proteins 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 238000006165 Knowles reaction Methods 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 1
- 108010006519 Molecular Chaperones Proteins 0.000 claims 1
- 102000005431 Molecular Chaperones Human genes 0.000 claims 1
- 101100067996 Mus musculus Gbp1 gene Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 102000003697 P-type ATPases Human genes 0.000 claims 1
- 108090000069 P-type ATPases Proteins 0.000 claims 1
- 208000009182 Parasitemia Diseases 0.000 claims 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 241000223821 Plasmodium malariae Species 0.000 claims 1
- 101710194807 Protective antigen Proteins 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 1
- 239000004473 Threonine Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000003321 amplification Effects 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- 108091008324 binding proteins Proteins 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000021164 cell adhesion Effects 0.000 claims 1
- 230000007969 cellular immunity Effects 0.000 claims 1
- 230000036755 cellular response Effects 0.000 claims 1
- 238000012761 co-transfection Methods 0.000 claims 1
- 230000001276 controlling effect Effects 0.000 claims 1
- 210000005220 cytoplasmic tail Anatomy 0.000 claims 1
- 230000001086 cytosolic effect Effects 0.000 claims 1
- 241001493065 dsRNA viruses Species 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 102000034356 gene-regulatory proteins Human genes 0.000 claims 1
- 108091006104 gene-regulatory proteins Proteins 0.000 claims 1
- 210000004602 germ cell Anatomy 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 229930195712 glutamate Natural products 0.000 claims 1
- 230000002440 hepatic effect Effects 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000007774 longterm Effects 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 210000004779 membrane envelope Anatomy 0.000 claims 1
- 210000003071 memory t lymphocyte Anatomy 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000006386 neutralization reaction Methods 0.000 claims 1
- 238000003199 nucleic acid amplification method Methods 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 230000003071 parasitic effect Effects 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 229940118768 plasmodium malariae Drugs 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 230000037452 priming Effects 0.000 claims 1
- 230000001681 protective effect Effects 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 210000003705 ribosome Anatomy 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 208000003265 stomatitis Diseases 0.000 claims 1
- 238000010361 transduction Methods 0.000 claims 1
- 230000026683 transduction Effects 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10290238.4 | 2010-05-03 | ||
| EP10290238.4A EP2385107B1 (en) | 2010-05-03 | 2010-05-03 | Lentiviral vector based immunological compounds against malaria |
| PCT/EP2011/056887 WO2011138251A1 (en) | 2010-05-03 | 2011-04-29 | Lentiviral vector based immunological compounds against malaria |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015233691A Division JP2016041076A (ja) | 2010-05-03 | 2015-11-30 | レンチウイルスベクターに基づくマラリアに対する免疫学的化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013527760A JP2013527760A (ja) | 2013-07-04 |
| JP2013527760A5 true JP2013527760A5 (cg-RX-API-DMAC7.html) | 2013-08-15 |
| JP5937574B2 JP5937574B2 (ja) | 2016-06-22 |
Family
ID=42731903
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013508445A Active JP5937574B2 (ja) | 2010-05-03 | 2011-04-29 | レンチウイルスベクターに基づくマラリアに対する免疫学的化合物 |
| JP2015233691A Pending JP2016041076A (ja) | 2010-05-03 | 2015-11-30 | レンチウイルスベクターに基づくマラリアに対する免疫学的化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015233691A Pending JP2016041076A (ja) | 2010-05-03 | 2015-11-30 | レンチウイルスベクターに基づくマラリアに対する免疫学的化合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US9109234B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2385107B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP5937574B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20130096164A (cg-RX-API-DMAC7.html) |
| CN (1) | CN103314104B (cg-RX-API-DMAC7.html) |
| BR (1) | BR112012027999A2 (cg-RX-API-DMAC7.html) |
| DK (1) | DK2385107T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2011138251A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9169304B2 (en) | 2012-05-01 | 2015-10-27 | Pfenex Inc. | Process for purifying recombinant Plasmodium falciparum circumsporozoite protein |
| CN103965320A (zh) * | 2013-01-29 | 2014-08-06 | 苏州偲聚生物材料有限公司 | 多肽、包含该多肽的检测器件和检测试剂盒 |
| CN105683383B (zh) * | 2013-06-03 | 2020-08-21 | 赛拉福柯蒂斯公司 | 含有I型MHC、II型MHC或β2微球蛋白上游启动子序列的慢病毒载体 |
| EP2878674A1 (en) | 2013-11-28 | 2015-06-03 | Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) | Stable episomes based on non-integrative lentiviral vectors |
| EP3087188A1 (en) * | 2013-12-23 | 2016-11-02 | Theravectys | Lyophilized lentiviral vector particles, compositions and methods |
| US10010607B2 (en) | 2014-09-16 | 2018-07-03 | Institut Curie | Method for preparing viral particles with cyclic dinucleotide and use of said particles for inducing immune response |
| CN106290840A (zh) * | 2015-05-13 | 2017-01-04 | 上海凯创生物技术有限公司 | 间日疟原虫乳胶法检测试剂盒 |
| CN105754962A (zh) * | 2016-01-07 | 2016-07-13 | 中南大学 | 一种单循环复制艾滋病毒样颗粒及其制备方法和应用 |
| CN108779473A (zh) | 2016-03-16 | 2018-11-09 | 法国居里学院 | 用于制备具有环二核苷酸的病毒颗粒的方法和所述颗粒用于治疗癌症的用途 |
| CA3024950A1 (en) * | 2016-05-19 | 2017-11-23 | The Trustees Of The University Of Pennsylvania | Synthetic malaria immunogens, combinations thereof, and their use to prevent and treat malaria infections |
| US11725035B2 (en) | 2016-08-09 | 2023-08-15 | Stipe Therapeutics Aps | Methods of treating a disorder associated with with insufficient stimulator of interferon genes (STING) activity |
| EP3357506A1 (en) * | 2017-02-02 | 2018-08-08 | Institut Pasteur | Multiple malaria pre-erythrocytic antigens and their use in the elicitation of a protective immune response in a host |
| EP3357504A1 (en) * | 2017-02-02 | 2018-08-08 | Institut Pasteur | Functional screening of antigenic polypeptides - use for the identification of antigens eliciting a protective immune response and for the selection of antigens with optimal protective activity |
| CN109251929A (zh) * | 2018-04-27 | 2019-01-22 | 杭州贝英福生物科技有限公司 | 一种干扰二化螟几丁质酶基因CsCht10的siRNA |
| US20210187089A1 (en) * | 2018-05-23 | 2021-06-24 | Institut Pasteur | Malaria pre-erythrocytic antigens as a fusion polypeptide and their use in the elicitation of a protective immune response in a host |
| EP3820997A4 (en) * | 2018-07-09 | 2022-09-21 | Board of Supervisors of Louisiana State University and Agricultural and Mechanical College | Viral-vectored vaccine for malaria |
| CN109022456B (zh) * | 2018-07-24 | 2021-03-02 | 江南大学 | 一种表达卵形疟原虫ama1蛋白的病毒疫苗的制备方法 |
| GB201906283D0 (en) * | 2019-05-03 | 2019-06-19 | Moredun Res Institute | Vector |
| AU2021337534A1 (en) * | 2020-09-01 | 2023-03-16 | The Trustees Of The University Of Pennsylvania | Improved generation of lentiviral vectors for T cell transduction using cocal envelope |
| US12304929B2 (en) * | 2021-04-12 | 2025-05-20 | Sk Bioscience Co., Ltd. | Recombinant RSV live vaccine strain and the preparing method thereof |
| JP2024517131A (ja) | 2021-04-20 | 2024-04-19 | アンスティテュ・クリー | 免疫療法における使用のための組成物及び方法 |
| JP2024514707A (ja) | 2021-04-20 | 2024-04-02 | アンスティテュ・クリー | 免疫療法における使用のための組成物及び方法 |
| CN116987157B (zh) * | 2023-09-27 | 2023-11-28 | 深圳华大生命科学研究院 | 一种弹状病毒包膜蛋白、含其的靶向慢病毒载体及其应用 |
| CN121005787B (zh) * | 2025-10-22 | 2025-12-26 | 南京鸿明生物科技有限公司 | 一种嵌合型包膜糖蛋白、其制备方法及涉及该包膜糖蛋白的包膜质粒、包装方法和试剂盒 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5766597A (en) * | 1991-03-07 | 1998-06-16 | Virogenetics Corporation | Malaria recombinant poxviruses |
| FR2777909B1 (fr) | 1998-04-24 | 2002-08-02 | Pasteur Institut | Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex |
| US8163893B2 (en) * | 2006-02-15 | 2012-04-24 | The Regents Of The University Of Caifornia | Pseudotyped retroviral vectors and methods of use thereof |
| PT2169073E (pt) | 1999-10-11 | 2014-02-20 | Pasteur Institut | Vectores para a preparação de composições imunoterapêuticas |
| CA2382832C (en) | 1999-10-12 | 2012-06-26 | Institut Pasteur | Lentiviral triplex dna, and vectors and recombinant cells containing lentiviral triplex dna |
| DK200201741A (da) | 2002-11-12 | 2003-09-16 | Statens Seruminstitut | Vaccine comprising chimeric malaria proteins derived from Plasmodium falciparum |
| EP1573012B1 (en) | 2002-12-17 | 2011-11-30 | Crucell Holland B.V. | Recombinant viral-based malaria vaccines |
| FR2872170B1 (fr) | 2004-06-25 | 2006-11-10 | Centre Nat Rech Scient Cnrse | Lentivirus non interactif et non replicatif, preparation et utilisations |
| US8158413B2 (en) | 2005-10-17 | 2012-04-17 | Institut Pasteur | Lentiviral vector-based vaccine |
| US8765146B2 (en) * | 2005-08-31 | 2014-07-01 | Genvec, Inc. | Adenoviral vector-based malaria vaccines |
| MX2010001379A (es) | 2007-08-03 | 2010-06-08 | Pasteur Institut | Vectores de tranferencia de gen lentiviral y sus aplicaciones medicinales. |
| UY31285A1 (es) * | 2007-08-13 | 2009-03-31 | Vacunas |
-
2010
- 2010-05-03 EP EP10290238.4A patent/EP2385107B1/en active Active
- 2010-05-03 DK DK10290238.4T patent/DK2385107T3/en active
-
2011
- 2011-04-29 JP JP2013508445A patent/JP5937574B2/ja active Active
- 2011-04-29 KR KR1020127031691A patent/KR20130096164A/ko not_active Withdrawn
- 2011-04-29 EP EP11716434A patent/EP2566956A1/en not_active Withdrawn
- 2011-04-29 WO PCT/EP2011/056887 patent/WO2011138251A1/en not_active Ceased
- 2011-04-29 US US13/695,683 patent/US9109234B2/en active Active
- 2011-04-29 CN CN201180027852.4A patent/CN103314104B/zh active Active
- 2011-04-29 BR BR112012027999A patent/BR112012027999A2/pt not_active Application Discontinuation
-
2015
- 2015-07-15 US US14/799,633 patent/US9822153B2/en active Active
- 2015-11-30 JP JP2015233691A patent/JP2016041076A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013527760A5 (cg-RX-API-DMAC7.html) | ||
| US9109234B2 (en) | Lentiviral vector based immunological compounds against malaria | |
| CN102482329B (zh) | 用辛德毕斯病毒包膜糖蛋白假型化的慢病毒载体 | |
| ES2963179T3 (es) | Vacunas contra el virus de la hepatitis b (VHB) y usos de las mismas | |
| Coutant et al. | A nonintegrative lentiviral vector-based vaccine provides long-term sterile protection against malaria | |
| MD3390430T2 (ro) | Antigenele virusului imunodeficienței umane, vectori, compoziții și metode de utilizare ale acestora | |
| Yusuf et al. | Adeno-associated virus as an effective malaria booster vaccine following adenovirus priming | |
| US11857611B2 (en) | Compositions and methods for generating an immune response to treat or prevent malaria | |
| CN102046785A (zh) | 基于慢病毒的免疫原性载体 | |
| Gilbert et al. | Ty virus-like particles, DNA vaccines and Modified Vaccinia Virus Ankara; comparisons and combinations | |
| Neukirch et al. | The potential of adenoviral vaccine vectors with altered antigen presentation capabilities | |
| Raska et al. | Delivery of DNA HIV-1 vaccine to the liver induces high and long-lasting humoral immune responses | |
| Reeder et al. | Strategic variants of CSP delivered as SynDNA vaccines demonstrate heterogeneity of immunogenicity and protection from Plasmodium infection in a murine model | |
| CN101394868A (zh) | 重组腺病毒5型/35型和痘病毒mva活病毒载体疫苗的联用诱导强大的免疫应答的方法 | |
| Schuldt et al. | Vaccine platforms combining circumsporozoite protein and potent immune modulators, rEA or EAT-2, paradoxically result in opposing immune responses | |
| US20220296703A1 (en) | Cobmination of hepatitis b virus (hbv) vaccines and anti-pd-1 or anti-pd-l1 antibody | |
| Sun et al. | Vesicular stomatitis virus-based vaccine targeting plasmodium blood-stage antigens elicits immune response and protects against malaria with protein booster strategy | |
| JP2022537324A (ja) | Ｂ型肝炎ウイルス（ｈｂｖ）ワクチンおよび抗ｐｄ－１抗体の組合せ | |
| Kumar et al. | mRNA-LNP expressing PfCSP and Pfs25, two leading vaccine candidates targeting infection and transmission of Plasmodium falciparum | |
| Xu et al. | vaccine targeting plasmodium blood-stage antigens elicits immune response and protects against malaria with protein | |
| Halbroth et al. | Salman | |
| WO2014176530A1 (en) | Vaccination methods | |
| Shahin et al. | Heterologous prime-boost immunisation regimens against infectious diseases | |
| EA045279B1 (ru) | Вакцины против вируса гепатита b (hbv) и их применение |